Description: A member of the Sackler family that owns OxyContin’s maker directed the company to put a premium on selling high dosages of its potentially addicting painkillers, according to new disclosures in a lawsuit.
Date: Jan 31, 2019
Questions for discussion:
- What does the article say to investors about risk?
- Is there any way to deal with this sort of risk?